Clinical trial · Observational
Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Company decision to terminate
Summary
Brief summary (as posted)
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006).This registry is specific to Surgeons (ONC003). Outcomes measures on lung cancer relapse and death from any cause will be collected.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Adenocarcinoma | Lung Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Percentage change from Pre-Test to Post-Test referral
- timeFrame
- 3 months
- description
- The percentage change from the recorded PRE-TEST referral by surgeon versus the POST-TEST referral following results of myPlan Lung Cancer testing
Secondary outcomes (4)
- measure
- Percentage change from the Pre-test referral to the 60-day Post-Test referral
- timeFrame
- 2 months
- description
- The percentage change from the recorded Pre-Test referral by surgeon versus the 60 day post-test actual referral attendance
- measure
- Percentage of patients at 60 days post test receiving treatment
- timeFrame
- 2 months
- description
- The percentage of patients at 60 day post-test who are receiving radiation and or chemotherapy treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of early stage non-small cell lung adenocarcinoma * Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the investigational site * Resection of tumor within previous 2 months of enrollment * ECOG performance of 0-2 * A minimum life expectancy of six months Exclusion Criteria: * Pre-operative radiation or chemotherapy for NSCLC * Post-operative radiation or chemotherapy for NSCLC * Enrollment in a separate clinical trial restricting treatment options * Unable to provide informed consent
References
Publications (0)
Data not yet available